The PSCI publishes Materiality Assessment of the Pharma Supply Chain
In the latest instalment of the PSCI blog on CPHI Online, The PSCI introduces the 2024 PSCI Supply Chain Materiality Assessment, the first public materialty assessment of the pharmaceutical supply chain they have worked on.
The 2024 PSCI Supply Chain Materiality Assessment focused on supply chains for the Pharmaceutical and Healthcare industries, taking into account the views of its own members, as well as a range of sources from outside the PSCI.
These assessments are conducted periodically by the PSCI, but this year the association decided to apply a double materiality approach, based on the methodology published by the European Financial Reporting Group (EFRAG), that scores issues against two categories: business or financial impacts, and planetary impacts.
The assessment results contain a number of key findings divided into six categories: ethics, human rights, health & safety, environment, materials, and community.
There are several notable new inclusions this year, including:
Ethics: responsible engagement on policy (lobbying) & substandard and falsified medicines
Human Rights: diversity and inclusion & housing conditions
Health & Safety: workplace hazards & biosafety
Environment: climate change resilience
Materials: traceability of raw materials
Community: communities’ human rights
Reflecting on the assessment, PSCI Chair & Global EH&S Supplier Operations and Business Development Lead at Viatris, Dr Deirdre O’Reilly, said:
“New regulations and investor demands are raising the bar for company reporting on supply chain responsibility. This year's assessment highlights the growing importance of robust supply chain programmes, encompassing a wider range of issues. It also reflects the changing nature of the industry’s products and markets.”
The assessment is intended to represent the sector as a whole, and is not reflective of each individual company. Pharma is a diverse industry and material issues for individual businesses will differ depending on a variety of factors like product mix, geography, ownership, etc. A full double materiality review would typically include rigorous quantification of impacts. As this is challenging to do at a sector level, this assessment from the PSCI used desk research along with member inputs to score issues using a framework aligned with EFRAG’s double materiality guidance.
Research resources for the assessment included:
- The latest legislation, reporting frameworks, and investor indices;
- Media reports, NGO activity, and other relevant reports and research;
- External stakeholder input including PSCI’s advisory panel and other partner organisations;
Finally, another vital part of the process was member inputs. These inputs came through ongoing and regular discussions within the PSCI’s own topic teams, as well as through the 2023 member consultation across all PSCI Principles topics. Throughout the assessment and scoring, a patient lens was applied, considering how patients could be impacted by substantially positive or negative handling of each issue.
The PSCI intends to use the results of this assessment to ensure that new and emerging topics are considered (and top issues given due focus in their activities), that the position of important stakeholders on supply chain responsibility topics is systematically understood, and finally that PSCI members’ responsibility programmes are covering all material issues.
For the 2024 PSCI Supply Chain Materiality Assessment, click here.
Related News
-
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News A Day in the Life of a Head of Quality Assurance and Regulatory Affairs
We are continuing to get to know the people working day-to-day behind the pharma companies shaping the industry, the ones who keep the wheels turning and ultimately bring better healthcare to the population; we are talking to the individuals at the hea... -
News Women in Pharma: Delivering personal and professional success
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Drug Patent Expiries: a steep cliff or opportunity for innovation?
The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future. -
News The 2024 Pharma Outsourcing Forecast: strategic partnerships across global landscapes
For the pharmaceutical industry, outsourcing drug development, manufacturing, and research operations to contract organisations is not just a passing trend – increasingly, the partnership between drug sponsor and drug vendor is one of vital impor... -
News A Day in the Life of a President and Chief Scientific Officer
We are continuing to get to know the people working day-to-day behind the pharma companies shaping the industry, the ones who keep the wheels turning and ultimately bring better healthcare to the population; we are talking to the individuals at the hea... -
News Special Edition Women in Pharma: Women’s health and the pharmaceutical industry
International Women’s Day is an annual celebration of women around the world every March 8. March also marks Women’s History Month. This March, our Women in Pharma series takes a look at how women’s healthcare has developed, and the r... -
News LEAP-ing into the future of pharma – the CPHI Middle East Vision
On March 6, 2024, the CPHI team hosted the Future of Pharma Forum at LEAP 2024, Saudi Arabia’s premier destination for tech leaders and innovators to meet and collaborate.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance